C. difficile Market Analysis, Size, Share & Growth Forecast 2026–2034

Rebyota RBX2660 Single-Enema FDA-Approved Fecal Microbiota Live Biotherapeutic 70.6 Versus 57.5 Percent 8-Week CDI Non-Recurrence Has Established the First FDA-Approved Microbiome Restoration Therapy for Recurrent CDI That Restores the Firmicutes-Dominated Protective Colonic Microbiome.Merck's bezlotoxumab demonstrated 38% relative reduction in recurrent CDI at 12 weeks when added to vancomycin or fidaxomicin in MODIFY I and MODIFY II across 2,655 patients, earning FDA approval as the first approved agent for CDI recurrence prevention through a mechanism that neutralises ToxB toxin responsible for colonic epithelial disruption. The commercial challenge for bezlotoxumab is identifying the high-risk patient population who benefit most from the single USD 3,500 infusion during their acute CDI episode, and IDSA guidance identifies hypervirulent ribotype 027, prior CDI episode, immunocompromised status, and age above 65 as the risk factors that concentrate benefit in the subgroup where the absolute recurrence reduction justifies the cost. Healthcare system analyses demonstrate cost-effectiveness of bezlotoxumab in high-risk CDI patients where CDI recurrence generates average additional costs of USD 40,000 per episode from hospitalisation, extended antibiotics, and nursing facility stays.

Vowst SER-109 Oral Fecal Microbiota Spore Capsule 88 Versus 60 Percent CDI Non-Recurrence From 3-Day 4-Capsule Course Has Provided the Oral Microbiome Restoration Alternative to the Rectal Enema That Requires Bowel Preparation and Clinical Setting Administration.Rebiotix's RBX2660 Rebyota and Seres Therapeutics's SER-109 Vowst received FDA approval in 2022 and 2023 as the first manufactured FMT products for recurrent CDI, achieving 70.6% and 88% CDI-free rates at 8 weeks respectively in PUNCH CD3 and ECOSPOR IV trials that exceed the 65-70% efficacy of conventional donor stool FMT from clinical programmes. The manufactured product approach eliminates the donor screening, pathogen testing, and endoscopic or colonoscopic delivery required for conventional FMT, enabling outpatient oral capsule (Vowst) or enema (Rebyota) administration that dramatically reduces the procedural complexity and infection risk of donor FMT programmes. The commercial positioning of Vowst and Rebyota competes against established hospital and gastroenterology group FMT programmes that generate institutional revenue from endoscopic FMT, requiring reimbursement parity with the colonoscopic procedure cost to achieve guideline-concordant prescribing.

Bezlotoxumab Zinplava Anti-Toxin B MODIFY Phase III 17 Versus 28 Percent Recurrence in High-Risk CDI Patients Has Established the Adjunctive Monoclonal Antibody Reducing Recurrence in the Prior CDI, Age Above 65, Immunocompromised, and Severe CDI High-Risk Patient.Astellas Pharma's fidaxomicin demonstrated 13.3% versus 24.0% recurrence rate versus vancomycin in OPT-80, and its narrow-spectrum activity targeting C. difficile without suppressing vancomycin-sensitive commensal Bacteroides and Lactobacillus preserves the intestinal microbiome diversity that provides colonisation resistance against CDI recurrence. The clinical evidence for fidaxomicin superiority in non-hypervirulent strains and in immunocompetent patients supports its use as the preferred first-line CDI treatment in ESCMID and IDSA guidelines that recommend fidaxomicin over vancomycin for initial episodes. The generic fidaxomicin launch following patent expiry and the entry of Dificid generic manufacturers has reduced the 10-day vancomycin versus fidaxomicin cost differential from approximately USD 3,000 to under USD 500, substantially improving the cost-effectiveness case for fidaxomicin standard use over vancomycin in first-episode CDI.

For related market intelligence, see the Mrsa Treatment Market.